Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial.
Fiche publication
Date publication
juin 2017
Journal
Blood cancer journal
Auteurs
Membres identifiés du Cancéropôle Est :
Pr FORNECKER Luc-Matthieu, Dr DAGUINDAU Etienne, Dr OJEDA-URIBE Mario
Tous les auteurs :
Hunault-Berger M, Maillard N, Himberlin C, Recher C, Schmidt-Tanguy A, Choufi B, Bonmati C, Carré M, Couturier MA, Daguindau E, Marolleau JP, Orsini-Piocelle F, Delaunay J, Tavernier E, Lissandre S, Ojeda-Uribe M, Sanhes L, Sutton L, Banos A, Fornecker LM, Bernard M, Bouscary D, Saad A, Puyade M, Rouillé V, Luquet I, Béné MC, Hamel JF, Dreyfus F, Ifrah N, Pigneux A
Lien Pubmed
Mots clés
Aged, Aged, 80 and over, Azacitidine, administration & dosage, Disease-Free Survival, Female, Humans, Lenalidomide, Leukemia, Myeloid, Acute, drug therapy, Maintenance Chemotherapy, Male, Middle Aged, Survival Rate, Thalidomide, administration & dosage
Référence
Blood Cancer J. 2017 06 2;7(6):e568